NCT05730205Active, not recruitingPhase 4
Effects of the Contraceptive Implant in Women With Sickle Cell Disease
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
The objective of this study is to measure the acceptability and impact of the progestin implant on frequency of vaso-occlusive crises, quality of life, and hematologic parameters in women with SCD.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- First submitted
- 6 Feb 2023
- Start date
- 2 Aug 2023
- Primary completion date
- Mar 2027
- Lead sponsor
- University of Pennsylvania
- Diseases
- Sickle cell disease
- NCT number
- NCT05730205
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 22
- From 2 Aug 2023 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Changes to sickle cell medications in the past 3 months
Other illness
- History of hematopoeitic stem cell transplantation
- Contraindications to use of Nexplanon device as per clinical standards (not including history of venous thromboemblosim \[VTE\])
Other
- Use of Depo Provera in the past 6 months
- Regular blood transfusions
- Currently pregnant or pregnant within the last month or seeking to become pregnant
- Currently breastfeeding
Who the study is looking for
- Female aged 18-45
- Diagnosis of sickle cell disease (SS, SB 0, SB+, SC)
- Report of at least 1 vaso-occlusive pain episode per month on average in the previous 6 months
- Willing to discontinue any hormonal contraception at the time of enrollment. Washout period of 1 month required for all hormonal contraception prior to enrollment in the study.
- Access to a device with text messaging capability
- Must be able to read and understand English
- Willing to comply with study procedures
Age in the registry: 18 years to 45 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Penn Medicine University City Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.